Neurobo Pharmaceuticals Inc
NASDAQ:NRBO
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1.6
6.52
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Neurobo Pharmaceuticals Inc
Neurobo Pharmaceuticals Inc
Total Liabilities
Neurobo Pharmaceuticals Inc
Total Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Neurobo Pharmaceuticals Inc
NASDAQ:NRBO
|
Total Liabilities
$9.2m
|
CAGR 3-Years
68%
|
CAGR 5-Years
25%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Total Liabilities
$137.4B
|
CAGR 3-Years
1%
|
CAGR 5-Years
15%
|
CAGR 10-Years
19%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Total Liabilities
$36.1B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
9%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Total Liabilities
$83.4B
|
CAGR 3-Years
14%
|
CAGR 5-Years
11%
|
CAGR 10-Years
6%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Total Liabilities
$6.6B
|
CAGR 3-Years
29%
|
CAGR 5-Years
24%
|
CAGR 10-Years
18%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Total Liabilities
$8.1B
|
CAGR 3-Years
8%
|
CAGR 5-Years
19%
|
CAGR 10-Years
21%
|
|
Neurobo Pharmaceuticals Inc
Glance View
NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in developing and commercializing multi-modal disease-modifying therapies. The company is headquartered in Boston, Massachusetts and currently employs 5 full-time employees. The company went IPO on 2016-08-05. The firm is engaged in the development and commercialization of therapeutics. The company is focused on four therapeutics programs designed to impact a range of indications in viral, neurodegenerative and cardiometabolic disease. The Company’s therapeutics programs include ANA001, NB-01, NB-02 and Gemcabene. Its ANA001, is an oral niclosamide formulation and was developed as a treatment for patients with moderate coronavirus disease (COVID-19). NB-01, which is primarily focused on the development of a treatment for painful diabetic neuropathy and treat a range of neuropathic conditions. Its NB-02, which treats the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of a protein called tau, and with amyloid beta plaque deposition. The Company’s Gemcabene, which is being assessed as an acute indication for COVID-19 treatments.
See Also
What is Neurobo Pharmaceuticals Inc's Total Liabilities?
Total Liabilities
9.2m
USD
Based on the financial report for Sep 30, 2024, Neurobo Pharmaceuticals Inc's Total Liabilities amounts to 9.2m USD.
What is Neurobo Pharmaceuticals Inc's Total Liabilities growth rate?
Total Liabilities CAGR 5Y
25%
Over the last year, the Total Liabilities growth was 88%. The average annual Total Liabilities growth rates for Neurobo Pharmaceuticals Inc have been 68% over the past three years , 25% over the past five years .
You don't have any saved screeners yet
